Vicarious Surgical Inc RBOT.N, RBOT.K is expected to show no change in quarterly revenue when it reports results on March 3 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Vicarious Surgical Inc is for a loss of $2.69 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Vicarious Surgical Inc is $11.75, below its last closing price of $11.80.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -2.56 | -2.55 | -2.90 | Missed | -13.5 |
Jun. 30 2024 | -2.81 | -2.77 | -2.59 | Beat | 6.7 |
Mar. 31 2024 | -2.81 | -2.85 | -3.00 | Missed | -5.3 |
Dec. 31 2023 | -3.73 | -3.75 | -1.80 | Beat | 52 |
Sep. 30 2023 | -3.95 | -4.27 | -3.00 | Beat | 29.8 |
Jun. 30 2023 | -4.44 | -4.27 | -3.60 | Beat | 15.8 |
Mar. 31 2023 | -4.05 | -4.05 | -6.30 | Missed | -55.6 |
Dec. 31 2022 | -5.40 | -5.20 | -2.70 | Beat | 48.1 |
This summary was machine generated February 28 at 11:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。